Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study is a research paper published in Journal of Clinical Investigation (2024). On theSindex it has a DataRank of 0.332. It has been cited 8 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
2.68 × 10⁻³
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
Siteman Retina Research Fund
Grant: GF0012047
Jeffrey T. Fort Innovation Fund
Grant: GF0003776
NIH
Grant: NHLBI R01HL129241
NIH
Grant: NINDS RF1NS116565
The Clayco Foundation
Grant: 3054-32706
NHLBI NIH HHS
Grant: R01 HL129241
NINDS NIH HHS
Grant: U24 NS107230
NINDS NIH HHS
Grant: R01 NS131480
NINDS NIH HHS
Grant: RF1 NS116565
National Institutes of Health
Grant: 1RF1NS116565-01
MR measured regional hypoxia as an early biomarker in cerebral small vessel disease
National Institutes of Health
Grant: 5R01HL129241-09
MR-Derived Cerebral Oxygen Metabolism underlying Ischemic Vulnerability in Sickle Cell Disease
FWCI
3.27
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals